EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis

Shimpei Yamashita iD, Hiroki Kawabata, Yuya Iwahashi, Satoshi Muraoka, Takahito Wakamiya, Fumiyoshi Kojima, Yasuo Kohjimoto, Shin-Ichi Murata, Isao Hara

IJU Case Reports · 2025-05 · 8 (3) · 223-226

DOI: 10.1002/iju5.70011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IJU Case Reports, online erschienen am 09.03.2025. Verfasst von Shimpei Yamashita und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Wakayama Medical University Wakayama Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

There is no clear evidence of the safety and efficacy of pembrolizumab plus lenvatinib combination therapy in patients on hemodialysis. This is the first report of a patient on hemodialysis to receive this combination therapy for metastatic renal cell carcinoma. Case Presentation A 60‐year‐old man on hemodialysis had cT3bN1M0 unclassified renal cell carcinoma. He received the combination therapy of pembrolizumab plus lenvatinib. Although the dose of lenvatinib was halved to 10 mg/day due to Grade 3 thrombocytopenia, 6 months later, the volumes of the primary lesion and lymph node metastasis were remarkably reduced.

Conclusion

Our case report suggests the feasibility of the combination therapy of pembrolizumab plus lenvatinib for patients with metastatic renal cell carcinoma who are undergoing hemodialysis.

Schlagwörter

Stichwörter der Autor:innen

hemodialysislenvatinibpembrolizumabrenal cell carcinomasafety

Autor:innen und Institutionen

  • Department of Urology Wakayama Medical University Wakayama Japan.
  • Department of Pathological Diagnosis Wakayama Medical University Wakayama Japan.

ORCID-Profile: Shimpei Yamashita

Zitieren

APA

Yamashita, S., Kawabata, H., Iwahashi, Y., Muraoka, S., Wakamiya, T., Kojima, F., Kohjimoto, Y., Murata, S. I., & Hara, I. (2025). Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis. IJU Case Reports, 8(3), 223-226. https://doi.org/10.1002/iju5.70011

Vancouver

Yamashita S, Kawabata H, Iwahashi Y, Muraoka S, Wakamiya T, Kojima F, et al. Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis. IJU Case Reports. 2025;8(3):223-226. doi:10.1002/iju5.70011

BibTeX
@article{Yamashita2025,
  author = {Yamashita, Shimpei and Kawabata, Hiroki and Iwahashi, Yuya and Muraoka, Satoshi and Wakamiya, Takahito and Kojima, Fumiyoshi and Kohjimoto, Yasuo and Murata, Shin-Ichi and Hara, Isao},
  title = {Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis},
  journal = {IJU Case Reports},
  year = {2025},
  volume = {8},
  number = {3},
  pages = {223--226},
  doi = {10.1002/iju5.70011}
}
Kostenlos starten →